Welcome to our dedicated page for Bio Rad Labs news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio Rad Labs stock.
Bio-Rad Laboratories, Inc. (BIO) delivers essential innovations in clinical diagnostics and life science research through its global operations. This dedicated news hub provides investors and industry professionals with timely access to official announcements, financial updates, and scientific advancements.
Discover comprehensive collection of press releases covering quarterly earnings, regulatory milestones, product launches, and strategic partnerships. Our curated feed ensures transparent access to BIO's operational developments across its dual focus areas: laboratory-quality diagnostic systems and cutting-edge research tools.
Key updates include innovations in digital PCR technology, quality control solutions for clinical testing, and advancements supporting biopharmaceutical development. Bookmark this page for direct access to primary-source information affecting BIO's market position and research impact.
Bio-Rad Laboratories (NYSE: BIO, BIOb) announced that key executives, including President and CEO Norman Schwartz, will participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference on June 2 at noon PT. The event will provide insights into the company's strategies and initiatives. A live webcast link will be available on their Investor Relations page.
Bio-Rad Laboratories reported Q1 2021 net sales of $726.8 million, a 27.1% increase from $571.6 million in Q1 2020. Life Science segment sales rose 61.3% to $366.5 million, driven by COVID-19 product demand. Clinical Diagnostics segment sales increased 5.4% to $358.5 million. Net income surged to $977.4 million ($32.38 per share) from $685.9 million ($22.72 per share) in the previous year. The company expects 5.5% to 6.0% currency-neutral revenue growth for the year. Gross margin slightly declined to 55.1% from 55.5%.
Bio-Rad Laboratories, Inc. (NYSE: BIO, BIOb) will announce its financial results for the first quarter of 2021 on April 29, 2021, after market close. A conference call to discuss these results is scheduled for 3 PM PT (6 PM ET). Investors can participate by calling 855-779-9068 in the U.S. or 631-485-4862 internationally, using the passcode 4692298. Additionally, the call will be available live via a webcast on the company's website.
Bio-Rad Laboratories (NYSE: BIO, BIOb) will participate in a virtual Fireside Chat at the Barclays Global Healthcare Conference on March 9 at 10:15 AM PST. Norman Schwartz (President and CEO), Andrew Last (Executive VP and COO), and Ilan Daskal (Executive VP and CFO) will represent the company. A live webcast will be accessible on their Investor Relations page at bio-rad.com.
Founded in 1952, Bio-Rad is a leader in life science research and clinical diagnostics, boasting over $2.5 billion in revenue in 2020 and 7,800 employees globally.
Bio-Rad Laboratories (NYSE: BIO, BIOb) will have its leadership team, including CEO Norman Schwartz, COO Andrew Last, and CFO Ilan Daskal, participate in a virtual Fireside Chat at Citi's 2021 Healthcare Services conference on February 24 at 11:25 AM PST. This event highlights Bio-Rad's commitment to innovation in life science research and clinical diagnostics. With over 65 years of experience and revenues surpassing $2.5 billion in 2020, Bio-Rad continues to advance healthcare solutions globally.
Bio-Rad Laboratories reported Q4 2020 results with net sales of $789.8 million, a 26.5% increase from Q4 2019. Life Science segment sales surged 77.1% to $428.5 million, largely driven by COVID-19-related demand. Gross margin improved to 58.3% from 52.9% year-over-year. Net income soared to $839.1 million, or $27.81 per share, compared to $553.5 million, or $18.31 per share in Q4 2019. Clinical Diagnostics segment saw a 5.1% decrease in sales. The company was awarded Emergency Use Authorization for new COVID-19 tests.
Bio-Rad Laboratories will announce its financial results for Q4 and full year 2020 on February 11, 2021, post-market. A conference call to discuss these results is scheduled for 3 PM PT (6 PM ET) the same day. Investors can access the call by dialing 855-779-9068 within the U.S. or 631-485-4862 internationally, using Conference ID: 8269933. The call will also be available via a webcast on the company’s Investor Relations page, which will remain accessible for one year.
Bio-Rad Laboratories (NYSE: BIO, BIOb) announced participation in a virtual Fireside Chat at the 39th Annual J.P. Morgan Healthcare Conference on January 11 at 1:30 PM PST. The event will feature President and CEO Norman Schwartz, COO Andrew Last, and CFO Ilan Daskal. Investors can access the live webcast through the Investor Relations section on bio-rad.com. Founded in 1952, Bio-Rad is a leader in life science research and clinical diagnostics, with over $2.3 billion in revenue in 2019 and a workforce of more than 8,000 employees globally.
Bio-Rad Laboratories (NYSE: BIO) has announced its 2023 outlook, projecting sales between $2.75 billion and $2.85 billion. The forecast reflects the company's strong product portfolio, including Droplet Digital PCR and clinical diagnostics. Bio-Rad expects a non-GAAP adjusted EBITDA margin of 23-24%, aided by operating leverage and improvements in capacity utilization. CEO Norman Schwartz emphasized a focus on balancing innovation with operational discipline to support organic growth and sustainability efforts.
Bio-Rad Laboratories, Inc. (NYSE: BIO) will announce its third-quarter 2020 financial results on October 29, 2020, after the market closes. A conference call is scheduled for 3 PM PT (6 PM ET) to discuss these results. The call can be accessed by dialing 855-779-9068 for U.S. callers or 631-485-4862 for international callers, using passcode 7061137. Additionally, interested parties can listen to the live webcast on the Investor Relations section of the company's website.
FAQ
What is the current stock price of Bio Rad Labs (BIO)?
What is the market cap of Bio Rad Labs (BIO)?
